"CA-19-9 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
| Descriptor ID |
D018395
|
| MeSH Number(s) |
D23.050.285.050.119 D23.050.301.290.544.119 D23.050.550.325.119 D23.050.705.230.544.119 D23.101.140.075.119
|
| Concept/Terms |
CA-19-9 Antigen- CA-19-9 Antigen
- Antigen, CA-19-9
- CA 19 9 Antigen
- CA 19.9 Antigen
- Antigen, CA 19.9
- Gastrointestinal Cancer Antigen
- Cancer Antigen, Gastrointestinal
- CA 19-9 Antigen
- Antigen, CA 19-9
- Antigen CA-19-9
- Antigen CA 19 9
- CA-19-9, Antigen
|
Below are MeSH descriptors whose meaning is more general than "CA-19-9 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CA-19-9 Antigen".
This graph shows the total number of publications written about "CA-19-9 Antigen" by people in this website by year, and whether "CA-19-9 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 5 | 8 | 13 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "CA-19-9 Antigen" by people in Profiles.
-
Effect of the coronavirus pandemic on tumor markers. J Med Virol. 2021 Sep; 93(9):5405-5408.
-
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. Eur J Cancer. 2019 04; 111:94-106.
-
Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg. 2018 05; 22(5):831-839.
-
Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open. 2017 12 26; 7(12):e018175.
-
CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Sci Rep. 2017 12 05; 7(1):16975.
-
Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma. J Med Ultrason (2001). 2018 Apr; 45(2):231-241.
-
Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):486-489.
-
Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease. Korean J Gastroenterol. 2017 Aug 25; 70(2):96-102.
-
Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017 Sep 26; 117(7):1017-1025.
-
Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer. JAMA Surg. 2017 07 19; 152(7):e171087.